Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Salwa Mansour has a total of 48 co-authors. Here are the top co-authors by number of shared publications:

  • Karelle Leroy

    Alzheimer and Other Tauopathies Research Group, ULB Neuroscience Institute (UNI), ULB Center for Diabetes Research (UCDR), Faculty of Medicine, Université Libre de Bruxelles, Brussels, Belgium

    5 shared publications
  • Kunie Ando

    Alzheimer and Other Tauopathies Research Group, ULB Center for Diabetes Research, Medical Faculty, ULB Neuroscience Institute, Université Libre de Bruxelles (ULB), 808 Route de Lennik, B-1070 Brussels, Belgium

    5 shared publications
  • Zehra Yilmaz

    Laboratory of Histology, Neuroanatomy and Neuropathology, Faculty of Medicine, Université Libre de Bruxelles, ULB Neuroscience Institute (UNI), Brussels, Belgium

    5 shared publications
  • Jean-Pierre Brion

    Alzheimer and Other Tauopathies Research Group, ULB Center for Diabetes Research, Medical Faculty, ULB Neuroscience Institute, Université Libre de Bruxelles (ULB), 808 Route de Lennik, B-1070 Brussels, Belgium

    4 shared publications
  • Robert De Decker

    Laboratory of Histology, Neuroanatomy and Neuropathology, Faculty of Medicine, ULB Neuroscience Institute, Université Libre de Bruxelles, Brussels, Belgium

    4 shared publications
  • Sarah Houben

    Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium

    3 shared publications

Latest Publications

  • Open Access

    PICALM Genetic Variant Alters mRNA Expression Without Affecting Protein Levels or Tau Spreading in Alzheimer’s Disease

    by Kunie Ando, Lidia Lopez-Gutierrez, Salwa Mansour, Zehra Yilmaz, Luce Dauphinot, Jan Verheijen, Gaëlle Fontaine, Carolina Quintanilla-Sánchez, Emmanuel Aydin, Emilie Doeraene, et al.

    Phosphatidylinositol-binding clathrin assembly protein (PICALM) is a clathrin adaptor essential for clathrin-mediated endocytosis. Genome-wide association studies (GWAS) have consistently identified PICALM as one of the most significant genetic susceptibility loci for late-onset sporadic Alzheimer’s disease (AD). However, the functional impact of the most validated AD-associated variant, rs3851179, remains unclear. Here, we examined PICALM mRNA and protein expression in post-mortem AD brains with reference to rs3851179 genotype. We found that PICALM mRNA levels were significantly increased in AD brains compared with controls, and that the protective rs3851179T allele was associated with reduced PICALM mRNA levels relative to the non-protective rs3851179C allele. In contrast, PICALM levels were significantly reduced in AD brain lysates compared with controls. PICALM expression did not significantly differ between carriers of the protective and non-protective alleles. Analysis of the mRNA-to-protein ratio revealed a significant dissociation between transcript and protein levels, suggesting relatively reduced protein expression efficiency in cases carrying the non-protective CC genotype. To assess whether reduced PICALM levels influence tau pathology, we used Picalm heterozygous knockout (Picalm+/−) mice, which express approximately 50% of the wild-type Picalm protein. Following stereotaxic injection of pathological tau extracted from AD brains, both wild-type and Picalm+/− mice developed tau pathology; however, the extent of tau accumulation did not significantly differ between genotypes. Together, these findings indicate that although PICALM protein level is reduced in AD, this reduction does not appear to affect tau propagation in this model. Therefore, the AD susceptibility associated with PICALM variant likely arises from mechanisms other than tau spread, possibly involving other aspects of autophagy, endocytic or vascular function.

  • Open Access

    Alteration of gene expression and protein solubility of the PI 5-phosphatase SHIP2 are correlated with Alzheimer’s disease pathology progression

    by Kunie Ando, Fahri Küçükali, Emilie Doeraene, Siranjeevi Nagaraj, Eugenia Maria Antonelli, May Thazin Htut, Zehra Yilmaz, Andreea-Claudia Kosa, Lidia Lopez-Guitierrez, Carolina Quintanilla-Sánchez, et al.

    A recent large genome-wide association study has identified EGFR (encoding the epidermal growth factor EGFR) as a new genetic risk factor for late-onset AD. SHIP2, encoded by INPPL1, is taking part in the signalling and interactome of several growth factor receptors, such as the EGFR. While INPPL1 has been identified as one of the most significant genes whose RNA expression correlates with cognitive decline, the potential alteration of SHIP2 expression and localization during the progression of AD remains largely unknown. Here we report that gene expression of both EGFR and INPPL1 was upregulated in AD brains. SHIP2 immunoreactivity was predominantly detected in plaque-associated astrocytes and dystrophic neurites and its increase was correlated with amyloid load in the brain of human AD and of 5xFAD transgenic mouse model of AD. While mRNA of INPPL1 was increased in AD, SHIP2 protein undergoes a significant solubility change being depleted from the soluble fraction of AD brain homogenates and co-enriched with EGFR in the insoluble fraction. Using FRET-based flow cytometry biosensor assay for tau-tau interaction, overexpression of SHIP2 significantly increased the FRET signal while siRNA-mediated downexpression of SHIP2 significantly decreased FRET signal. Genetic association analyses suggest that some variants in INPPL1 locus are associated with the level of CSF pTau. Our data support the hypothesis that SHIP2 is an intermediate key player of EGFR and AD pathology linking amyloid and tau pathologies in human AD.


  • Open Access

    Intravenous Injection of PHF-Tau Proteins From Alzheimer Brain Exacerbates Neuroinflammation, Amyloid Beta, and Tau Pathologies in 5XFAD Transgenic Mice

    by Sarah Houben, Marie-Ange de Fisenne, Kunie Ando, Virginie Vanden Dries, Luc Poncelet, Zehra Yilmaz, Salwa Mansour, Robert De Decker, Jean-Pierre Brion, Karelle Leroy

    Alzheimer’s disease (AD) is characterized by the accumulation in the brain of intraneuronal aggregates of abnormally and hyperphosphorylated tau proteins and of extracellular deposits of amyloid-β surrounded by dystrophic neurites. Numerous experimental models have shown that tau pathology develops in the brain after intracerebral injection of brain homogenates or pathological tau [paired helical filaments (PHF)-tau)] from AD brains. Further investigations are however necessary to identify or exclude potential extracerebral routes of tau pathology transmission, e.g., through the intravascular route. In this study, we have analyzed the effect of intravenous injection of PHF-tau proteins from AD brains on the formation of tau and amyloid pathologies in the brain of wild-type (WT) mice and of 5XFAD mice (an amyloid model). We observed that 5XFAD mice with a disrupted blood–brain barrier showed increased plaque-associated astrogliosis, microgliosis, and increased deposits of Aβ40 and Aβ42 after intravenous injection of PHF-tau proteins. In addition, an increased phosphotau immunoreactivity was observed in plaque-associated dystrophic neurites. These results suggest that blood products contaminated by PHF-tau proteins could potentially induce an exacerbation of neuroinflammation and AD pathologies.


  • Picalm reduction exacerbates tau pathology in a murine tauopathy model

    by Kunie Ando, Robert De Decker, Cristina Vergara, Zehra Yilmaz, Salwa Mansour, Valérie Suain, Kristel Sleegers, Marie-Ange de Fisenne, Sarah Houben, Marie-Claude Potier, et al.

    Genome-wide association studies (GWAS) have identified PICALM as one of the most significant susceptibility loci for late-onset Alzheimer’s disease (AD) after APOE and BIN1. PICALM is a clathrin-adaptor protein and plays critical roles in clathrin-mediated endocytosis and in autophagy. PICALM modulates brain amyloid ß (Aß) pathology and tau accumulation. We have previously reported that soluble PICALM protein level is reduced in correlation with abnormalities of autophagy markers in the affected brain areas of neurodegenerative diseases including AD, sporadic tauopathies and familial cases of frontotemporal lobar degeneration with tau-immunoreactive inclusions (FTLD-tau) with mutations in the microtubule-associated protein tau (MAPT) gene. It remains unclarified whether in vivo PICALM reduction could either trigger or influence tau pathology progression in the brain. In this study, we confirmed a significant reduction of soluble PICALM protein and autophagy deficits in the post-mortem human brains of FTLD-tau-MAPT (P301L, S364S and L266V). We generated a novel transgenic mouse line named Tg30xPicalm+/− by crossing Tg30 tau transgenic mice with Picalm-haploinsufficient mice to test whether Picalm reduction may modulate tau pathology. While Picalm haploinsufficiency did not lead to any motor phenotype or detectable tau pathology in mouse brains, Tg30xPicalm+/− mice developed markedly more severe motor deficits than Tg30 by the age of 9 months. Tg30xPicalm+/− had significantly higher pathological tau levels in the brain, an increased density of neurofibrillary tangles compared to Tg30 mice and increased abnormalities of autophagy markers. Our results demonstrate that Picalm haploinsufficiency in transgenic Tg30 mice significantly aggravated tau pathologies and tau-mediated neurodegeneration, supporting a role for changes in Picalm expression as a risk/sensitizing factor for development of tau pathology and as a mechanism underlying the AD risk associated to PICALM.


  • Amyloid-β pathology enhances pathological fibrillary tau seeding induced by Alzheimer PHF in vivo

    by Cristina Vergara, Sarah Houben, Valérie Suain, Zehra Yilmaz, Robert De Decker, Virginie Vanden Dries, Alain Boom, Salwa Mansour, Karelle Leroy, Kunie Ando, et al.

    Neuropathological analysis in Alzheimer’s disease (AD) and experimental evidence in transgenic models overexpressing frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17) mutant tau suggest that amyloid-β pathology enhances the development of tau pathology. In this work, we analyzed this interaction independently of the overexpression of an FTDP-17 mutant tau, by analyzing tau pathology in wild-type (WT), 5xFAD, APP−/− and tau−/− mice after stereotaxic injection in the somatosensory cortex of short-length native human AD-PHF. Gallyas and phosphotau-positive tau inclusions developed in WT, 5xFAD, and APP−/− but not in tau−/− mice. Ultrastructural analysis demonstrated their intracellular localization and that they were composed of straight filaments. These seeded tau inclusions were composed only of endogenous murine tau exhibiting a tau antigenic profile similar to tau aggregates in AD. Insoluble tau level was higher and ipsilateral anteroposterior and contralateral cortical spreading of tau inclusions was more important in AD-PHF-injected 5xFAD mice than in WT mice. The formation of large plaque-associated dystrophic neurites positive for oligomeric and phosphotau was observed in 5xFAD mice injected with AD-PHF but never in control-injected or in non-injected 5xFAD mice. An increased level of the p25 activator of CDK5 kinase was found in AD-PHF-injected 5xFAD mice. These data demonstrate in vivo that the presence of Aβ pathology enhances experimentally induced tau seeding of endogenous, wild-type tau expressed at physiological level, and demonstrate the fibrillar nature of heterotopically seeded endogenous tau. These observations further support the hypothesis that Aβ enhances tau pathology development in AD through increased pathological tau spreading.


  • Open Access

    Amyloid pathology enhances seeding and propagation of fibrillar endogenous non-mutant tau in vivo

    by Cristina Vergara, Sarah Houben, Valérie Suain, Zehra Yilmaz, Robert De Decker, Salwa Mansour, Alain Boom, Karelle Leroy, Kunie Ando, Jean-Pierre Brion

    The topographical development of tau pathology in Alzheimer’s Disease (AD) progresses by following neuroanatomically connected areas, suggesting that spreading of tau pathology occurs by transmission of abnormal tau between synaptically connected cells. Both, neuropathological analysis in AD and experimental evidence in transgenic models overexpressing FTDP-17 mutant tau, suggest that amyloid pathology can accelerate the development of tau pathology, yet the involved mechanisms are not understood. To investigate a potential role of Aß pathology in accelerating the spreading of tau pathology independently of the overexpression of a FTDP-17 mutant tau, we compared development of tau pathology after stereotaxic injection in the somatosensory cortex of short-length native human PHF. We used four mouse lines, namely non-transgenic wild-type, APP/PS1 overexpressing human mutant APP and PS1, APP knock-out mice and tau knock-out mice. Gallyas and phosphotau positive grain-like tau inclusions developed in wild-type, APP/PS1 and APP knock-out mice but not in tau knock-out mice. Ultrastructural analysis demonstrated that these tau grains were intracellular and were made of 20 nm straight filaments. These tau grains seeded by human PHF-tau were composed only of endogenous murine tau. Ipsilateral anteroposterior and contralateral spreading of these tau grains in the cortex was more important in APP/PS1 than in wild-type mice. Importantly, the formation of enlarged, tau positive, plaque-associated dystrophic neurites was observed in APP/PS1 mice injected with human PHF but never in non-injected APP/PS1 mice. These data demonstrate in vivo that the presence of Aß pathology enhances experimentally induced tau seeding of endogenous, wild-type tau expressed at physiological level, and demonstrate the fibrillar nature of heterotopically seeded endogenous tau. These observations strongly support the hypothesis that a cross-talk between Aß and tau can enhance the development of tau pathology in AD through increased tau spreading. Summary: Alzheimer's disease is the main cause of dementia, causing progressive memory decline and behavioral changes affecting daily tasks. It is characterised by the appearance of two abnormal lesions called amyloid plaques and tangles, responsible for the neuronal loss during the disease. Amyloid plaques are composed of a small protein called amyloid-beta, and tangles are formed by the aggregation of another protein called tau. Here we study how amyloid-beta affects the aggregation of tau to form tangles in genetically modified animal models.